Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Supplemental material
  • Footnotes
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Corrigendum Open Access | 10.1172/JCI162359

CDK4 is an essential insulin effector in adipocytes

Sylviane Lagarrigue, Isabel C. Lopez-Mejia, Pierre-Damien Denechaud, Xavier Escoté, Judit Castillo-Armengol, Veronica Jimenez, Carine Chavey, Albert Giralt, Qiuwen Lai, Lianjun Zhang, Laia Martinez-Carreres, Brigitte Delacuisine, Jean-Sébastien Annicotte, Emilie Blanchet, Sébastien Huré, Anna Abella, Francisco J. Tinahones, Joan Vendrell, Pierre Dubus, Fatima Bosch, C. Ronald Kahn, and Lluis Fajas

Find articles by Lagarrigue, S. in: PubMed | Google Scholar

Find articles by Lopez-Mejia, I. in: PubMed | Google Scholar

Find articles by Denechaud, P. in: PubMed | Google Scholar

Find articles by Escoté, X. in: PubMed | Google Scholar

Find articles by Castillo-Armengol, J. in: PubMed | Google Scholar

Find articles by Jimenez, V. in: PubMed | Google Scholar

Find articles by Chavey, C. in: PubMed | Google Scholar

Find articles by Giralt, A. in: PubMed | Google Scholar

Find articles by Lai, Q. in: PubMed | Google Scholar

Find articles by Zhang, L. in: PubMed | Google Scholar

Find articles by Martinez-Carreres, L. in: PubMed | Google Scholar

Find articles by Delacuisine, B. in: PubMed | Google Scholar

Find articles by Annicotte, J. in: PubMed | Google Scholar

Find articles by Blanchet, E. in: PubMed | Google Scholar

Find articles by Huré, S. in: PubMed | Google Scholar

Find articles by Abella, A. in: PubMed | Google Scholar

Find articles by Tinahones, F. in: PubMed | Google Scholar

Find articles by Vendrell, J. in: PubMed | Google Scholar

Find articles by Dubus, P. in: PubMed | Google Scholar

Find articles by Bosch, F. in: PubMed | Google Scholar

Find articles by Kahn, C. in: PubMed | Google Scholar

Find articles by Fajas, L. in: PubMed | Google Scholar

Published July 1, 2022 - More info

Published in Volume 132, Issue 13 on July 1, 2022
J Clin Invest. 2022;132(13):e162359. https://doi.org/10.1172/JCI162359.
© 2022 Lagarrigue et al. This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Published July 1, 2022 - Version history
View PDF

Related article:

CDK4 is an essential insulin effector in adipocytes
Sylviane Lagarrigue, … , C. Ronald Kahn, Lluis Fajas
Sylviane Lagarrigue, … , C. Ronald Kahn, Lluis Fajas
Research Article Endocrinology Metabolism

CDK4 is an essential insulin effector in adipocytes

  • Text
  • PDF
Abstract

Insulin resistance is a fundamental pathogenic factor that characterizes various metabolic disorders, including obesity and type 2 diabetes. Adipose tissue contributes to the development of obesity-related insulin resistance through increased release of fatty acids, altered adipokine secretion, and/or macrophage infiltration and cytokine release. Here, we aimed to analyze the participation of the cyclin-dependent kinase 4 (CDK4) in adipose tissue biology. We determined that white adipose tissue (WAT) from CDK4-deficient mice exhibits impaired lipogenesis and increased lipolysis. Conversely, lipolysis was decreased and lipogenesis was increased in mice expressing a mutant hyperactive form of CDK4 (CDK4R24C). We performed a global kinome analysis and found that mice lacking Cdk4 had impaired insulin signaling in the adipose tissue. Interestingly, our results demonstrated that insulin activates the cyclin D3-CDK4 complex, which, in turn, phosphorylates the insulin receptor substrate 2 (IRS2) at the Ser 388, likely creating a positive feedback loop to maintain adipocyte insulin signaling. Furthermore, we found that CCND3 expression and IRS2 serine 388 phosphorylation are increased in human obese subjects. Together, our results demonstrate that CDK4 is a major regulator of insulin signaling in WAT.

Authors

Sylviane Lagarrigue, Isabel C. Lopez-Mejia, Pierre-Damien Denechaud, Xavier Escoté, Judit Castillo-Armengol, Veronica Jimenez, Carine Chavey, Albert Giralt, Qiuwen Lai, Lianjun Zhang, Laia Martinez-Carreres, Brigitte Delacuisine, Jean-Sébastien Annicotte, Emilie Blanchet, Sébastien Huré, Anna Abella, Francisco J. Tinahones, Joan Vendrell, Pierre Dubus, Fatima Bosch, C. Ronald Kahn, Lluis Fajas

×

Original citation: J Clin Invest. 2016;126(1):335–348. https://doi.org/10.1172/JCI81480

Citation for this corrigendum: J Clin Invest. 2022;132(13):e162359. https://doi.org/10.1172/JCI162359

Following the publication of this article, the authors realized that errors were made during manuscript preparation. Figure 3J and Figure 3L, illustrating the insulin sensitivity test in the Cdk4nc and CdkR24C/R24C mice, respectively, were not representative. Specifically, independent experiments using mice with different ages were aggregated in the results. The correct Figure 3J now shows insulin tolerance tests (ITTs) in 24-week-old Cdk4+/+ and Cdk4nc (n = 5), and the correct Figure 3L shows ITT in 30-week-old CdkR24C/R24C mice (n = 5–11). In contrast with the original published data, the corrected data do not show statistical significance in the insulin sensitivity tests.

In addition, the quantification in Figure 7B did not correspond with the immunoblot image in Figure 7A. Therefore, new quantification is now shown in Figure 7B. Data from one control mouse (lane 5) blot indicates no response to insulin, as assessed by the absence of IRS and AKT phosphorylation, which signifies failure of insulin injection. Consequently, this was removed from the quantification shown in Figure 7B. Due to the sample size limitation, statistical analyses in Figure 7, B and D, were removed.

For clarity, the authors have added information to the figure legends about the ages of mice for additional experiments shown in Figures 1, 3, 4, 5, and 7 and Supplemental Figures 1, 2, and 5.

The Journal has published an online version of the original article with the unreliable statements crossed out and the modified text highlighted in red (Supplemental File, Redaction). The authors have confirmed the accuracy of the data and that the corrected paper is reliable.

The authors regret the errors and the possible confusion generated to the readers of the Journal.

Supplemental material

View Supplemental data

Footnotes

See the related article at CDK4 is an essential insulin effector in adipocytes.

Version history
  • Version 1 (July 1, 2022): Electronic publication

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Supplemental material
  • Footnotes
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts